MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

15.71 2.95

Buy Sell

Overview

Share price change

24h

Current

Min

15.11

Max

15.72

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	5.766 63.808
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+27.06% upside

Market Stats
By TradingEconomics
Market Cap	2.6B
Previous open	12.76
Previous close	15.71

News Sentiment

By Acuity

50%

150 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

14.24 / 14.78 Support & Resistance

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 kwi 2026, 23:48 UTC

Major News Events

Crude Oil, Refined Product Prices Moving Higher Amid Renewed Tensions in Strait of Hormuz -- OPIS

19 kwi 2026, 23:36 UTC

Major News Events

NAB Raises Provisions as Australian Banks Face Iran Risks -- Update

19 kwi 2026, 22:47 UTC

Major News Events

National Australia Bank Adds $215 Million in Iran-Driven Credit Provisions

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

19 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

19 kwi 2026, 23:49 UTC

Market Talk

Major News Events

Gold, Silver Decline Amid Renewed Inflation Concerns -- Market Talk

19 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

19 kwi 2026, 23:38 UTC

Major News Events

U.A.E. Asks U.S. About a Wartime Financial Lifeline -- Update

19 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Oil Climbs on Renewed Tensions Over Strait of Hormuz -- Market Talk

19 kwi 2026, 23:12 UTC

Major News Events

Spot Gold Falls 1.2%, Spot Silver Drops 1.6% on Renewed Middle East Tensions

19 kwi 2026, 23:10 UTC

Major News Events

Front-Month Brent Crude Oil Futures Rise 5.8% to $95.64 per Barrel

19 kwi 2026, 23:09 UTC

Major News Events

Front-Month WTI Crude Oil Futures Climb 7.2% to $89.86 per Barrel

19 kwi 2026, 23:08 UTC

Major News Events

Front-Month Crude Oil Futures Climb on Renewed Tensions Over Strait of Hormuz

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Cancer Biotech -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Announcement Could Come As Soon As Monday, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Be Worth Over $2B Plus Additional Milestones, Sources Say -- WSJ

19 kwi 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Nears Deal for Kelonia Therapeutics, Sources Say -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Central Bank Governor Khaled Mohamed Balama Raised Swap Idea With Treasury Secretary Scott Bessent in Washington -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

Emiratis Portrayed Swap Proposal as Precautionary and Preliminary in Case Iran War Drags On -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

The U.A.E. Has Opened Talks with U.S. for Currency Swap -- WSJ

19 kwi 2026, 20:03 UTC

Major News Events

U.A.E. Asks U.S. for a Wartime Financial Lifeline -- WSJ

18 kwi 2026, 01:00 UTC

Major News Events

As Economic Pressures Mount, Will Iran or the U.S. Blink First? -- WSJ

17 kwi 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 kwi 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 kwi 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 kwi 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 kwi 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 kwi 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

27.06% upside

12 Months Forecast

Average 20 USD 27.06%

High 20 USD

Low 20 USD

Based on 1 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Technical Score

By Trading Central

14.24 / 14.78Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

150 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.